Glioblastoma multiforme (GBM) is a highly aggressive brain cancer. The standard course of treatment is a combination of radiation and chemotherapy. Even with the dual treatment, the 5-year survival rate of patients with GBM is between 4-7%. Therefore, there is an urgent need to develop novel therapies to increase the survivorship. A possible cause of the low survival rate for GBM patients is the presence of neoplastic cells with efficient DNA repair abilities. These cells have been shown to be resilient against chemotherapy and radiation. They often continue to grow unchecked leading to lethal secondary tumor disease.

XRN2 is upregulated in GBMs as compared to normal and other brain cancer types. XRN2 is a 5’-3’ exonuclease that resolve DNA:RNA hybrids (R loops) that arise during transcription, especially at the 3’ end of genes. R-loop biology can affect gene expression by modulating the access of genes to transcription factors, miRNA transcription, and methylation status of genes. Our preliminary data have shown that loss of XRN2 sensitizes to a variety of DNA damaging agents but in particular ionizing radiation. In addition, XRN2 is required for DNA repair in specifically DNA double stranded break repair.

To understand how XRN2 modulates DNA repair, we conducted RNA-Seq analyses of two GBM cell lines with and without XRN2 expression and found that XRN2 can regulate genes involved in DNA repair pathway. We have conducted a mini-cherry picked screen of the XRN2 targets and found at least 6 genes to be required for DNA double stranded break repair. A subset of the 6 genes were also found to be sensitive to DNA damage agents such as ionizing radiation, etoposide, and Parp-1 inhibition. One XRN2-target is POLA2. We have found that POLA2 is required for homologous recombination and non-homologous end-joining repair, the two major repair pathways for DNA double stranded breaks. Another XRN2- target is CENPI. We found that CENPI is required for homologous recombination repair and not non-homologous end-joining; showing that XRN2 targets have differential impacts in DNA repair.

Our goal is to develop a patient signature that can better predict patient outcome and if possible a new synergetic treatment plan to increase the efficacy of radio-therapies.